INTEGRATED BIOPHARMA INC
Close on Oct 19, 2026
- Market cap
- $5.59M
- P/E (TTM)
- –
- Dividend yield
- –
About Integrated Biopharma
Pharmaceutical Preparations, SIC 2834
Integrated BioPharma, Inc. manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products. The company operates primarily through two segments: Contract Manufacturing and Other Business Lines. Contract Manufacturing produces dietary supplements for distributors, multilevel marketing firms, and specialized health-care providers. The Other Business Lines segment provides warehousing and order fulfillment services while distributing select raw materials. Its customer base is situated mainly in the United States and Luxembourg, with significant business generated from major contract manufacturing accounts.
The company operates its corporate executive offices in Hillside, New Jersey. Its manufacturing and commercial operations are supported by domestic infrastructure, including leased warehouse facilities and equipment, to supply its business partners across its primary geographic markets in the United States and abroad.
Summary of the business section of Integrated Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INTEGRATED BIOPHARMA INC
- Founded
- 1995
- Headquarters
- Hillside, NJ
- Address
- 225 Long Avenue, Building 15 07205
- Phone
- (973) 926-0816
- Website
- ibiopharma.com
- Employees
- 134, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- CBIZ CPAs P.C., Morristown, New Jersey
Stock & identifiers
- Ticker
- INBP
- Exchange
- OTC
- IPO date
- Oct 30, 1996
- Shares outstanding
- 31M, Sep 23, 2026
- Public float
- $3.43M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1016504
- CUSIP
- 45811V105
- ISIN
- US45811V1052
- EIN
- 22-2407475
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christina Kay | Co-Chief Executive Officer, Director | 4,883,979 |
| Sheppard Riva | Co-Chief Executive Officer | 4,899,679 |
| Dina Masi | Chief Financial Officer | 347,200 |
| Robert Canarick | Director | 234,233 |
| William H. Milmoe | Director | 2,512,751 |
| Damon DeSantis | Director | 10,497,641 |
| Eric J. Friedman | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $325.04K | $318.64K | $334.58K | $72 | – |
| FY2024 | $331.30K | $315.19K | $343.72K | $42 | – |
| FY2023 | $306.74K | $296.14K | $330.79K | $66 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 23, 2026, we had approximately 134 full-time employees, including 99 who are members of the local unit of the Teamsters Union and are covered by a collective bargaining agreement which expires on September 30, 2026.”
Corporate history
Events identified from SEC filings